On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details
FridayJun 23, 2017 1:18 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 23, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: QUIK 17.85% – News: Selected by two developers for EOS™ S3; enters collaboration agreement AMRS 7.60% – News: Moves on momentum of recent partnership with the Government of Queensland IEGH 7.27% – News: Sells entirety of OneMain investment for $3.4M AKTX 6.50% – News: Presents today at the 22nd Congress of the EHA SUNW 3.95% – News: Installing a 1.06 MW solar project for Demas Farms MGTI 2.97% – News: Enters agreement with Bit5ive…

Continue Reading

FridayJun 23, 2017 1:17 pm

NetworkNewsBreaks – BlastGard International, Inc. (BLGA) At a Glance

BlastGard International Inc. (OTC: BLGA) specializes in manufacturing and distributing protective products for military and law enforcement, operating under two segments: BlastGard Defense Group and Highcom Security. The company’s chief focus is providing blast effects mitigation solutions for customers in the commercial sector, as well as for military, law enforcement and government agencies, with its sights set on becoming a recognized industry leader in providing environmentally responsible solutions for protecting lives and structures from the hazards associated with fire and explosions. “BlastGard is a blast mitigation specialist with proprietary material proven to effectively mitigate blasts and suppress fires resulting from explosions.…

Continue Reading

FridayJun 23, 2017 1:15 pm

NetworkNewsBreaks – BioDelivery Sciences (NASDAQ: BDSI) Receives Health Canada Approval of BELBUCA®; Plans to Launch In Early 2018

BioDelivery Sciences (NASDAQ: BDSI) this morning said that Health Canada has issued a Notice of Compliance (NOC) approving BELBUCA® for the management of opioid responsive pain severe enough to require daily, continuous, long-term treatment for which alternative options are inadequate. Approval is an important milestone for the company as it intends to commercialize BELBUCA in Canada through a partner. The launch of BELBUCA in Canada is expected in early 2018. "We believe BELBUCA offers important and distinctive advantages for those dealing with chronic pain, and we look forward to engaging with a commercial partner in Canada and for availability of…

Continue Reading

FridayJun 23, 2017 1:13 pm

NetworkNewsBreaks – ParkerVision, Inc. (NASDAQ: PRKR) Shares Plunge on Holding Decision in Infringement Case Against Apple (NASDAQ: AAPL)

Shares of ParkerVision (NASDAQ: PRKR) plunged 14% mid-day on news that the Regional Court of Munich is holding its decision in the ParkerVision v. Apple (NASDAQ: AAPL) infringement case until after the German Federal Patent Court rules on the associated pending nullity action. Similarly, the company’s final resolution in its German case against LG is pending the same action. The company expects a preliminary nullity decision before the end of 2017. “We remain optimistic that the Federal Patent Court will come to that conclusion yet this year enabling us to request the Regional Court to issue an enforceable injunction against…

Continue Reading

FridayJun 23, 2017 11:44 am

NetworkNewsBreaks – AVEO Oncology (NASDAQ: AVEO) Shares Skyrocket on CHMP’s Recommendation to Approve Tivozanib

AVEO Oncology (NASDAQ: AVEO) shares soared over 80% this morning on news that FOTIVDA™ has been recommended for approval as a treatment for patients with advanced renal cell carcinoma (RCC) by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency. The CHMP's recommendation is referred to the European Commission, which is anticipated to make its final decision in approximately 67 days. Approval of FOTIVDA™ would also result in R&D reimbursement and milestone payments for the company. “If the European Commission grants marketing approval for tivozanib, it would trigger a $4 million research…

Continue Reading

ThursdayJun 22, 2017 1:48 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on June 22, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: TROV 16.23% – News: Enters agreement with a worldwide biopharmaceutical company to provide Trovera® ctDNA biomarker tests GBSN 10.00% – News: Closes $2.7M Offering of Units PRTO 7.69% – News: Announces $22M Private Placement SUNW 5.67% – News: Installing a 760 kW solar construction project for Empire Farms in 2017 IVFH 5.00% – News: Reaches warrant exchange agreement with its largest institutional investor BGRP 4.62% – News: Holds election of directors at annual stockholders’…

Continue Reading

ThursdayJun 22, 2017 1:48 pm

NetworkNewsBreaks – Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) Ramps Up Exploration Efforts as China Refined Metals Production Continues to Decline

Available zinc concentrate continues to decline in China, driving an increase in zinc imports in the country. Various factors are credited for this, including falling demand for steel galvanization in China and a nationwide crackdown on industrial pollution. The entire world is similarly feeling the zinc shortage in the wake of major mine closures in Australia and Ireland, and Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) has strategically stepped up its own exploration activities to help meet the growing global demand for zinc imports. “In a recent press release (http://nnw.fm/2k1MI), the company reported that China boosted its refined zinc imports…

Continue Reading

ThursdayJun 22, 2017 1:45 pm

NetworkNewsBreaks – Positive Media Attention Recognizes InMed Pharmaceuticals’ (IMLFF) Operational Developments, Leadership Team

Ongoing media coverage continues to recognize and highlight the achievements of InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a preclinical biopharmaceutical company focused on developing therapies through research and development into the pharmacology of cannabinoids and drug delivery systems. The company was featured as a “Cannabis Runner” by Insider Financial earlier this year, and Forbes also more recently released an article calling InMed “more than just another cannabis drug company.” “Although the company’s pipeline is expected to generate a significant amount of attention in 2018, InMed Pharmaceuticals’ manufacturing system and database are catching the eye of investors and biotech companies. THC and…

Continue Reading

ThursdayJun 22, 2017 1:39 pm

NetworkNewsBreaks – Moxian (NASDAQ: MOXC) Aims for $25M Revenues in 2018, Leverages High Gross Margin and Existing SME Customer Base in China’s O2O Market

Investors will find a high-risk/high-reward opportunity in China’s online-to-offline (O2O) marketplace through Moxian, Inc. (NASDAQ: MOXC), a development-stage company currently executing a marketing strategy of converting its two O2O platforms from unpaid to paid. Based in Shenzhen, China, Moxian has a gross margin of 77.4 percent, which is the second-highest among its significantly higher market cap competitors, according to a SeeThruEquity research report (http://nnw.fm/dee5W). “SeeThruEquity notes that MOXC believes it can achieve a revenue total of $25 million in 2018. The company anticipates revenue of $11 million in 2017. Key to achieving its profit goals is MOXC’s high profit margins…

Continue Reading

ThursdayJun 22, 2017 1:38 pm

NetworkNewsBreaks – DelMar Pharmaceuticals (NASDAQ: DMPI) Shares Rise on IRB Approval for VAL-083 STAR-3 GBM Trial

DelMar Pharmaceuticals (NASDAQ: DMPI) shares are moving 21% higher today on news that the company has Institutional Review Board (IRB) approval to conduct its pivotal phase 3 study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3). IRBs are required under FDA regulations to review all human subject research to guarantee that the rights and welfare of human subjects are protected at all times. The VAL-083 STAR-3 GBM trial and all relevant study related materials were critically examined by the leading independent institutional review board and approved without any modifications. "We are pleased to remain on track to open enrollment in this trial…

Continue Reading

Contact us: 212.418.1217